Factors at Play Alexionâ€™s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).During the first quarter, based on preclinical data supporting the role of complement in COVID-19 and preliminary clinical evidence from approximately 100 patients, Alexion initiated a phase III study, investigating the use of Ultomiris in adults with COVID-19, who are hospitalized with severe pneumonia or acute respiratory distress symptom.